`
`For over 30 years, our mission has been to use the power of science to bring new medicinesto patients... over
`and overagain.
`
`Regeneron (NASDAQ: REGN) is a leading biotechnology companythatinvents life-trans forming
`medicines for people with serious diseases. Founded and led for over 30 years by physician-
`scientists, our unique ability to repeatedly and consistently translate science into medicine hasled
`to nine FDA-approved treatments and numerous product candidates in development, nearly all of
`which were homegrown in our laboratories. Our medicines and pipeline are designed to help
`patients with eye diseases,allergic and inflammatory diseases, cancer, cardiovascular and
`metabolic diseases, pain, hematologic diseases, infectious diseases and rare diseases.
`
`Regeneronis accelerating and improving the traditional drug development process through our
`proprietary VelociSuite® technologies, such as Velocimmune®, which uses unique genetically
`humanized mice to produceoptimized fully human antibodies and bispecific antibodies, and
`through ambitious research initiatives such as the Regeneron Genetics Center®, whichis
`conducting one of the largest genetics sequencing efforts in the world.
`
`Mylan v. Regeneron
`IPR2021-00881
`U.S. Pat. 9,254,338
`Exhibit 2246
`
`Every day, we apply¢
`technologiesandrele:
`people with serious diseaSt
`Th
`
`
`Followus: W in fFL> 1/4
`
`2020 wasa challenging butinspiring RegeneronNews:Oct22nd
`
`
`
`year: from creating a new medicine in Dupixent® (dupilumab)isthe
`record time while advancing a diverse
`First Biologic to Significantly
`pipeline to delivering needed medicines
`ReduceItch and Skin Lesionsin
`despite pandemic conditions.
`Phase 3 Trial for Prurigo
`
`m=
`Bes
`CaF
`
`Nodularis, Demonstrating the Role
`
`Exhibit 2246
`
`Page 01 of 04
`
`Exhibit 2246
`Page 01 of 04
`
`
`
`Regeneron by the numbers
`
`30+
`years of scientific leadership
`
`OK+
`employees worldwide
`
`employees with an MD, PhD
`or PharmD degree
`
`consecutive year as one of
`Fast Company Best
`Workplaces for Innovators
`
`ranking in Science
`magazine's global Top
`Employer surveyfor six of the
`past nine years
`
`volunteers for virtual Day for
`Doing Good 2020
`
`9
`
`FDA-approved medicines
`
`98%
`
`of our waste diverted from
`
`landfill, surpassing our 2025
`global responsibility goal
`
`~100%
`of drug candidates invented
`and developed in-house
`
`30+
`
`exomes sequenced to date
`
`peer-reviewed publications in
`2020
`
`product candidatesin clinical
`development across multiple
`therapeutic areas
`
`Honors and awards
`
`Fast Company:Best Workplacesfor Innovators, 2021
`
`Great Place To Work: Fortune 100 Best Companies to WorkFor, 2021
`
`Great Place to Work Ireland: Best Workplaces, 2021
`
`Great Place to Work Ireland: Best Workplaces for Women, 2021
`
`Fast Company: World Changing Ideas (Pandemic Response), 2021
`
`IDEA Pharma: Pharmaceutical Invention Index, 2021
`
`Science: Top Employer, 2020
`
`Fortune: Change the World, 2020
`
`Forbes: JUST Companies, 2020
`
`Dow JonesSustainability World Index, 2020
`
`Dow JonesSustainability North American Index, 2020
`
`Newsweek: America’s Most Responsible Companies, 2020
`
`Civic 50: Most Community-Minded Companies in the Nation, 2020 Great Places to Work: Best Workplacein Ireland, 2020
`
`Exhibit 2246
`
`Page 02 of 04
`
`2/4
`
`Exhibit 2246
`Page 02 of 04
`
`
`
`Led by science
`
`Weare the only biopharma companyfounded andled by physician-scientists since the
`beginning, more than three decades ago. From ourfirst days, science was and remains our
`central guiding principle. Our leadership includes multiple Nobel Laureates and five members
`of the National Academy of Sciences, and weare oneofthe first companies to form a Science
`and Technology Committee as an integral componentofits Board, a practice which has since
`becomeindustry standard.
`
`secrasneancrrasI
`
`>
`
`Featured perspectives
`
`The stories and opinions behind our work.
`
`meNemaseaef
`
`Sn oesaeTTTWATSS Homo0)a
`:
`Nee 3 ET lol)
`Soon MRee icse lar
`Eelerr
`eeeeda s leseL)
`
`SS EM le
`Senior Vice President, Corporate
`Communications and Citizenship
`
`A look back
`
`Science isn’t easy and new medicines aren't made over night. Decadesof investment and
`perseverance have broughtus to where wearetoday.
`
`Exhibit 2246
`
`Page 03 of 04
`
`3/4
`
`Exhibit 2246
`Page 03 of 04
`
`
`
`Contact us
`See our U.S. and Europeanlocations and contact information.
`
`A broad
`THD|
`collaborations
`
`Learn about our clinical-stage research
`partnerships and see how we're changing
`the landscape of medicine.
`
`oz:
`
`Industrial
`Operations and
`Product Supply
`
`Grounded in excellence and driven to
`continuously improve, our industry-
`leading l|OPS team is responsible for the
`production of our many medicines.
`
`eeicacauncomeanaus
`
`
`
`
`
`EXPLOREOPERATIONSOUR
`
`
`
`ae
`
`;
`
`5
`
`ie
`
`COVID-19PROGRAMANTIBODY
`
`Copyright © 2021 Regeneron Pharmaceuticals Inc.All rights reserved. All trademarks mentioned are the property oftheir respective owners.
`
`REGENERON termsotlse _SacialMediaTermsofTSS06):9NNO12117
`
`SCIENCE TO MEDICINE’
`Engagement
`CAREERS >
`y Ha] ffolieTHMelyPrivacyNotice
`
`1:11
`
`,
`
`
`
`Exhibit 2246
`
`Page 04 of 04
`
`Exhibit 2246
`Page 04 of 04
`
`